成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> CAS DataBase List >>Ensitrelvir

Ensitrelvir

CAS No.
2647530-73-0
Chemical Name:
Ensitrelvir
Synonyms
Ensitrelvir;(E)-6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione;Ensitrelvir (S-217622);S-217622-002;WIDELY Ensitrelvir;S-217622 (Ensitrelvir);Ensitrelvir Intermediates;6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione;intrapulmonary replication,Virus Protease,COVID-19,S217622,oral,SARS-CoV,Ensitrelvir,SARS coronavirus,S-217622,variant,S 217622,Inhibitor,inhibit;6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazinane-2,4-dione
CBNumber:
CB610473546
Molecular Formula:
C22H17ClF3N9O2
Molecular Weight:
531.88
MDL Number:
MOL File:
2647530-73-0.mol
Last updated:2024-11-20 11:41:24

Ensitrelvir Properties

Boiling point 696.2±65.0 °C(Predicted)
Density 1.65±0.1 g/cm3(Predicted)
solubility DMSO:160.0(Max Conc. mg/mL);300.82(Max Conc. mM)
form A crystalline solid
pka 5.19±0.20(Predicted)
color White to light yellow
InChIKey QMPBBNUOBOFBFS-UHFFFAOYSA-N
SMILES N1(CC2=CC(F)=C(F)C=C2F)C(=NC2C(Cl)=CC3C(C=2)=CN(C)N=3)NC(=O)N(CC2N=CN(C)N=2)C1=O
FDA UNII PX665RAA3H

Ensitrelvir Chemical Properties,Uses,Production

Description

A clinical candidate for treating COVID-19, Ensitrelvir (a nonproprietary name for S-217622), which was discovered through a research collaboration between Shionogi & Co., Ltd. and Hokkaido university, as the first nonpeptidic, noncovalent CLpro inhibitor. Ensitrelvir exhibited significant potent antiviral activity and high bioavailability arising from a favorable drug metabolism and pharmacokinetic (DMPK) profile as a once-daily oral medicine to treat COVID-19.

Mechanism of action

Like Paxlovid, Ensitrelvir also targets the 3CL protease (3CLpro). These two oral drugs are designed to block the activity of the SARS-CoV-2-3CL protease, thereby blocking the replication of the novel coronavirus.  It became the first Japanese domestic pill to treat COVID-19 and the third to be regulatorally approved in February 2022 in Japan.[1]

Side effects

The clinical trial results also showed that after taking Ensiprevir, symptoms such as runny nose, nasal congestion, sore throat, cough, and dyspnea were greatly improved, with minimal side effects. And it has a significant inhibitory effect on the proliferation of the novel coronavirus strain of Omicron.

Synthesis

A practical route to Ensitrelvir: The unprecedented strategy utilizing a meta-cresolyl moiety enhanced the stability of intermediate compounds and enabled scalable manufacturing of 1. The 6-step longest linear sequence (from 26) delivers the target molecule in 35.1% yield. This overall yield was improved by approximately 7-fold compared to the earlier process used in the early research and development stage (4.8%). Our convergent approach to the synthesis of 1 made the manufacturing process concise, streamlined, and short. Direct crystallization was achieved in 9 out of the 12 steps, thus establishing a greener process without silica-gel column chromatographic purification. In addition, the present practical process settled all the issues that made large-scale synthesis difficult, i.e., removal of corrosive acid by evaporation and the generation of noxious odors from thiol derivatives.[2]
Ensitrelvir

Regulations

The U.S. Food and Drug Administration (FDA) granted Fast Track designation to Ensitrelvir for COVID-19. FDA Fast Track designation is designed to facilitate the development and expedite the review of potential new therapies that treat severe conditions and fulfill an unmet medical need. Ensitrelvir was approved in Singapore in November 2023 based on the Special Access Route application. Ensitrelvir remains an investigational drug outside of Japan and Singapore. In addition, the brand name Xocova? has not been approved for use outside of Japan and Singapore and pertains only to the approved drug in Japan and Singapore.

References

[1] YOTSUYANAGI H, OHMAGARI N, DOI Y, et al. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial[C]. 2023: 0. DOI:10.1101/2023.07.11.23292264.
[2] TAKAHIRO KAWAJIRI*, TAKAYUKI TSURITANI    Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir[J]. ACS Central Science, 2023, 9 4: 836-843. DOI:10.1021/acscentsci.2c01203.

Ensitrelvir Preparation Products And Raw materials

Raw materials

Preparation Products

Ensitrelvir Suppliers

Global( 107)Suppliers
Supplier Tel Email Country ProdList Advantage
Chongqing Chemdad Co., Ltd
+86-023-6139-8061 +86-86-13650506873 sales@chemdad.com China 39894 58
Jinan Jianfeng Chemical Co., Ltd 		0531-88110457; +8615562555968 info@pharmachemm.com China 251 58
TargetMol Chemicals Inc. 		+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 32161 58
ANHUI WITOP BIOTECH CO., LTD 		+8615255079626 eric@witopchemical.com China 23541 58
Zhejiang J&C Biological Technology Co.,Limited 		+1-2135480471 +1-2135480471 sales@sarms4muscle.com China 10473 58
RR Scientific LLC 		+86-13917743231 sales@rrscientific.com United States 878 58
Nantong HI-FUTURE Biology Co., Ltd. 		+undefined18051384581 sales@chemhifuture.com China 3135 58
TargetMol Chemicals Inc. 		support@targetmol.com United States 38631 58
HangZhou RunYan Pharma Technology Co.,LTD. 		+8618882027439 sales2@runyanpharma.com China 302 58
Hebei Miaoyin Technology Co.,Ltd 		+86-17367732028 +86-17367732028 kathy@hbyinsheng.com China 3512 58

Related articles

  • Ensitrelvir: an oral antiviral drug
  • Ensitrelvir fumaric acid is an oral SARS-CoV-2 3C-like protease inhibitor that has shown antiviral effects against multiple SA....
  • Aug 6，2024

View Lastest Price from Ensitrelvir manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
ensitrelvir pictures 2024-12-22 ensitrelvir
2647530-73-0
 US $0.00 / g 1g 99 1000kg HangZhou RunYan Pharma Technology Co.,LTD.
Ensitrelvir pictures 2024-12-20 Ensitrelvir
2647530-73-0
 US $20.00 / kg 1kg 99% purity 20t Jinan Jianfeng Chemical Co., Ltd
Ensitrelvir pictures 2024-11-19 Ensitrelvir
2647530-73-0
 US $50.00-115.00 / mg 99.81% 10g TargetMol Chemicals Inc.
  • ensitrelvir pictures
  • ensitrelvir
    2647530-73-0
  • US $0.00 / g
  • 99
  • HangZhou RunYan Pharma Technology Co.,LTD.
  • Ensitrelvir pictures
  • Ensitrelvir
    2647530-73-0
  • US $20.00 / kg
  • 99% purity
  • Jinan Jianfeng Chemical Co., Ltd
  • Ensitrelvir pictures
  • Ensitrelvir
    2647530-73-0
  • US $50.00-115.00 / mg
  • 99.81%
  • TargetMol Chemicals Inc.
1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)- WIDELY Ensitrelvir S-217622-002 Ensitrelvir (S-217622) (E)-6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione Ensitrelvir/1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)- intrapulmonary replication,Virus Protease,COVID-19,S217622,oral,SARS-CoV,Ensitrelvir,SARS coronavirus,S-217622,variant,S 217622,Inhibitor,inhibit S-217622 (Ensitrelvir) Ensitrelvir Intermediates Ensitrelvir 6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazinane-2,4-dione 2647530-73-0 C22H17ClF3N9O2 API